Review
Subject Category: Clinical Trials
Molecular Therapy (2007) 15 6, 1042–1052. doi:10.1038/sj.mt.6300162
Prostate Cancer Gene Therapy Clinical Trials
Svend O Freytag1, Hans Stricker2, Benjamin Movsas1 and Jae Ho Kim1
- 1Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan, USA
- 2Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan, USA
Correspondence: Svend O. Freytag, Department of Radiation Oncology, Henry Ford Health System, One Ford Place 5D, Detroit, Michigan 48202, USA. E-mail: sfreyta1@hfhs.org
Received 4 February 2007; Accepted 1 March 2007; Published online 3 April 2007.
Abstract
Despite recent advances in early detection and treatment, prostate cancer is still the second leading cause of cancer death in men in the United States, and approximately 27,000 men will die from it this year. Better treatments are needed for aggressive forms of localized disease and hormone-refractory metastatic disease. Recently, several gene therapy strategies have generated provocative results in early-stage clinical trials, raising the possibility that gene therapy may have the potential to affect both localized and metastatic disease. Much work lies ahead. Nevertheless, for the time being, these studies provide hope that gene therapy may someday earn a place in the management of prostate cancer.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Phase I Trial of Replication-competent Adenovirus-mediated Suicide Gene Therapy Combined with IMRT for Prostate CancerMolecular Therapy Original Article
Phase I Trial of Replication-competent Adenovirus-mediated Suicide Gene Therapy Combined with IMRT for Prostate CancerMolecular Therapy Original Article
Five-year Follow-up of Trial of Replication-competent Adenovirus-mediated Suicide Gene Therapy for Treatment of Prostate CancerMolecular Therapy Original Article
See all 36 matches for Research